Nilotinib

Nilotinib Reactions 1680, p253 - 2 Dec 2017 Intracranial stenosis of the internal carotid artery: case report A 74-year-old woman developed intracranial stenosis of the internal carotid artery during treatment with nilotinib [dosage and route not stated]. The woman, who was diagnosed with chronic myeloid leukaemia (CML), initially received treatment with imatinib for three and a half year, which was later switched to nilotinib. During switch to nilotinib, no abnormality at the intracranial internal carotid artery (ICA) was observed. After two and a half year of nilotinib initiation, transient ischaemic attack (TIA) like transient hemiplegia was observed. Magnetic resonance angiography (MRA) revealed narrowing of basilar artery and left intracranial ICA. The woman’s nilotinib treatment was ceased and was switched to bosutinib. Bosutinib treatment was discontinued due to impairment in hepatic function of unknown cause. Dasatinib was also administered, but was stopped due to repeat episodes of right transient hemiplegia. She was started on dual antiplatelet therapy including aspirin and clopidogrel, which proved ineffective to control TIA. She was not able to sit upright due to haemodynamic impairment of the cerebral vascular circulation, which was confirmed by single photon emission computed tomography (SPECT). Subsequently, she underwent intracranial stent placement and cerebral vascular revascularisation was confirmed on SPECT. She had no further TIAs and neurological deficits, and bosutinib treatment was able to be started again. Author comment: "Herein, we report a case of a 74-year- old male CML patient with intracranial stenosis of the internal carotid artery developed during treatment with nilotinib". Ozaki T, et al. Intracranial stenting for nilotinib treatment-associated cerebrovascular stenosis in chronic myeloid leukemia. Interventional Neuroradiology 23: 527-530, No. 5, 1 Oct 2017. Available from: URL: http:// doi.org/10.1177/1591019917710810 - Japan 803284230 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Nilotinib

Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/nilotinib-0W0dt7fKE6
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-017-39184-1
Publisher site
See Article on Publisher Site

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial